Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

New data shows Valortim antibody enhances human T cell response to B. anthracis

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010.

25 Feb 2010

Enzyme can allow nerve cells in brain to grow and form complex networks: Study

Brain researcher Hiroshi Kawabe has discovered the workings of a process that had been completely overlooked until now, and that allows nerve cells in the brain to grow and form complex networks. The study shows that an enzyme which usually controls the destruction of protein components has an unexpected function in nerve cells: it controls the structure of the cytoskeleton and thus ensures that nerve cells can form the tree-like extensions that are necessary for signal transmission in the brain.

20 Feb 2010

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe.

18 Feb 2010

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Model Metrics has launched Pharma2GO Spring '10, a comprehensive sales force automation solution specifically designed for the pharmaceutical and life science industries that extends the power of Salesforce CRM to mobile devices.

10 Feb 2010

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Northwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.

8 Feb 2010

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

For the first time, researchers from the University of Pennsylvania School of Medicine have found that three different degenerative brain disorders are linked by a toxic form of the same protein. The protein, called Elk-1, was found in clumps of misshaped proteins that are the hallmarks of Parkinson's disease, Alzheimer's disease, and Huntington's disease.

3 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC’s lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.

21 Jan 2010

Study identifies new mechanism that causes allergic response in people

WHAT: A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema) and food allergy.

21 Jan 2010

Top pharmaceutical companies choose Cegedim Dendrite's cMDM solution

Cegedim Dendrite today announced that four prominent Life Sciences companies have contracted for its Customer Master Data Management (cMDM) solution, Nucleus as a Service, within the last four months. Three of the four are among the world’s top-25 pharmaceutical companies and the fourth is a mid-sized specialty pharmaceutical company. Cegedim Dendrite is the leading provider of Customer Relationship Management (CRM), Marketing, Regulatory Compliance and Data Optimization solutions designed specifically for the Life Sciences industry.

19 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

New evidence suggests amyloid beta plays a critical role in synaptic failure

The early stages of Alzheimer's disease are thought to occur at the synapse, since synapse loss is associated with memory dysfunction. Evidence suggests that amyloid beta (Aβ) plays an important role in early synaptic failure, but little has been understood about Aβ's effect on the plasticity of dendritic spines.

29 Dec 2009

Cegedim Dendrite and Ping Identity announce new partnership deal

Cegedim Dendrite and Ping Identity today announced a partnership to enable Internet Single Sign-On security for Cegedim Dendrite’s flagship Customer Relationship Management (CRM) suite, Mobile Intelligence.

22 Dec 2009

New stem cell based technology may eliminate brain cancer

Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing.

18 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

AIDS develops more rapidly in individuals who express HLA B*35-Px, shows study

Immune proteins called HLA molecules help to activate killer T cell responses against pathogens. But according to a study that will be published online on December 14th in the Journal of Experimental Medicine (www.jem.org), one particular group of HLA molecules cripples this activation, perhaps explaining why HIV-infected individuals who express these HLAs progress to AIDS more rapidly than others.

15 Dec 2009

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Geron Corporation today announced the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

New data shows Valortim antibody enhances human T cell response to B. anthracis

Enzyme can allow nerve cells in brain to grow and form complex networks: Study

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

Cytheris broadens patent protection for recombinant human interleukin-7

IMUC’s ICT-107 vaccine product candidate targets cancer stem cells

Study identifies new mechanism that causes allergic response in people

Top pharmaceutical companies choose Cegedim Dendrite's cMDM solution

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

New evidence suggests amyloid beta plays a critical role in synaptic failure

Cegedim Dendrite and Ping Identity announce new partnership deal

New stem cell based technology may eliminate brain cancer

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

AIDS develops more rapidly in individuals who express HLA B*35-Px, shows study

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in